|
RU2086544C1
(ru)
|
1991-06-13 |
1997-08-10 |
Хоффманн-Ля Рош АГ |
Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
|
|
US5820915A
(en)
|
1996-06-27 |
1998-10-13 |
Bioavailability Systems, L.L.C. |
Method for the preparation of a first-pass effective citrus-derived substance and product thereof
|
|
US6124477A
(en)
|
1996-06-27 |
2000-09-26 |
Bioavailability Systems, Llc |
Anti-first-pass effect compounds
|
|
US5990154A
(en)
|
1997-05-30 |
1999-11-23 |
Bioavailability Systems, L.L.C. |
Anti-first-pass effect compounds and citrus extract
|
|
US6248776B1
(en)
|
1997-08-26 |
2001-06-19 |
Bioavailability Systems, L.L.C. |
Anti-first-pass effect compounds
|
|
US20040058982A1
(en)
|
1999-02-17 |
2004-03-25 |
Bioavailability System, Llc |
Pharmaceutical compositions
|
|
US6063809A
(en)
|
1997-08-26 |
2000-05-16 |
Bioavailability Systems, Llc |
Anti-first-pass effect compounds
|
|
US5993887A
(en)
|
1998-06-29 |
1999-11-30 |
Bioavailability Systems, L.L.C. |
Safe citrus juice and process for preparation
|
|
WO2004037827A1
(en)
|
2000-10-20 |
2004-05-06 |
Bioavailability Systems, Llc |
Synthesis of spiro ortho esters, spiro ortho carbonates, and intermediates
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
JP2007528423A
(ja)
|
2004-03-11 |
2007-10-11 |
セコイア、ファーマシューティカルズ、インコーポレイテッド |
耐性防止レトロウイルスプロテアーゼ阻害薬
|
|
US7378441B2
(en)
|
2004-05-07 |
2008-05-27 |
Sequoia Pharmaceuticals, Inc. |
Resistance-repellent retroviral protease inhibitors
|
|
US20090281114A1
(en)
|
2008-05-08 |
2009-11-12 |
Fabre-Kramer Pharmaceuticals, Inc. |
Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction
|
|
CL2009001152A1
(es)
|
2008-05-13 |
2009-10-16 |
Array Biopharma Inc |
Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
|
|
MX354412B
(es)
|
2011-06-10 |
2018-03-05 |
Merck Patent Gmbh |
Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton.
|
|
US8466159B2
(en)
*
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
|
TWI599356B
(zh)
|
2012-09-26 |
2017-09-21 |
安羅格製藥有限責任公司 |
抑制突變型ｃ－ｋｉｔ的方法
|
|
MA38260B1
(fr)
|
2012-12-18 |
2018-04-30 |
Almirall Sa |
Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
|
|
US9458124B2
(en)
|
2013-02-06 |
2016-10-04 |
Wayne State University |
Substituted pyran derivatives
|
|
WO2014164543A1
(en)
|
2013-03-13 |
2014-10-09 |
The Regents Of The University Of Michigan |
Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
|
|
US11596636B2
(en)
|
2014-01-14 |
2023-03-07 |
The Trustees Of The University Of Pennsylvania |
Tailored combinatorial epigenetic therapies for P53 gain-of-function tumors
|
|
US20170119769A1
(en)
|
2014-06-10 |
2017-05-04 |
The Trustees Of The University Of Pennsylvania |
Scaffolds for inhibitors of menin-mll interactions
|
|
AU2015301746A1
(en)
*
|
2014-08-13 |
2017-02-16 |
Celgene Corporation |
Combination therapy for treating cancer
|
|
CN105732636B
(zh)
|
2014-12-30 |
2020-04-21 |
广东东阳光药业有限公司 |
杂芳化合物及其在药物中的应用
|
|
HK1246593A1
(zh)
|
2015-06-04 |
2018-09-14 |
Kura Oncology, Inc. |
用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
|
|
AU2016378579A1
(en)
|
2015-12-22 |
2018-06-14 |
Vitae Pharmaceuticals, Inc. |
Inhibitors of the menin-MLL interaction
|
|
US10869868B2
(en)
|
2016-01-26 |
2020-12-22 |
Memorial Sloan Kettering Cancer Center |
Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
|
|
PH12018501955B1
(en)
|
2016-03-16 |
2024-01-24 |
Kura Oncology Inc |
Bridged bicyclic inhibitors of menin-mll and methods of use
|
|
JP6991585B2
(ja)
|
2016-05-02 |
2022-01-12 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
メニン阻害剤としてのピペリジン
|
|
ES2990061T3
(es)
*
|
2016-05-10 |
2024-11-28 |
C4 Therapeutics Inc |
Degronímeros espirocíclicos para la degradación de proteínas diana
|
|
WO2017214367A1
(en)
*
|
2016-06-10 |
2017-12-14 |
Vitae Pharmaceuticals, Inc. |
Inhibitors of the menin-mll interaction
|
|
AU2017326006B2
(en)
|
2016-09-16 |
2021-10-28 |
Vitae Pharmaceuticals, LLC. |
Inhibitors of the menin-MLL interaction
|
|
WO2018175746A1
(en)
|
2017-03-24 |
2018-09-27 |
Kura Oncology, Inc. |
Methods for treating hematological malignancies and ewing's sarcoma
|
|
JP7307729B2
(ja)
|
2017-12-20 |
2023-07-12 |
ヤンセン ファーマシューティカ エヌ．ベー． |
メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤
|
|
JP7060694B2
(ja)
*
|
2018-01-18 |
2022-04-26 |
アレイ バイオファーマ インコーポレイテッド |
Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
|
|
EP3774731A4
(en)
|
2018-03-30 |
2021-11-24 |
The Regents Of The University Of Michigan |
PIPERIDINE COMPOUNDS AS COVALENT MENINE INHIBITORS
|
|
AU2019337547A1
(en)
|
2018-09-13 |
2021-03-18 |
Merck Sharp & Dohme Llc |
Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
|
|
JP2022503792A
(ja)
|
2018-09-26 |
2022-01-12 |
クラ オンコロジー，インク． |
メニン阻害剤を用いた血液悪性腫瘍の処置
|
|
SG11202106304RA
(en)
|
2018-12-31 |
2021-07-29 |
Biomea Fusion Llc |
Irreversible inhibitors of menin-mll interaction
|
|
EP4132932A4
(en)
|
2020-04-07 |
2024-04-17 |
Syndax Pharmaceuticals, Inc. |
COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF
|
|
US20240238291A1
(en)
|
2021-05-12 |
2024-07-18 |
Syndax Pharmaceuticals, Inc. |
Combinations for treatment of cancer
|
|
IL308476A
(en)
|
2021-05-14 |
2024-01-01 |
Syndax Pharmaceuticals Inc |
Inhibitors of the menin-mil interaction
|
|
TW202320796A
(zh)
|
2021-08-11 |
2023-06-01 |
美商拜歐米富士恩股份有限公司 |
用於糖尿病的menin-mll相互作用之共價抑制劑
|
|
CN118234497A
(zh)
|
2021-12-15 |
2024-06-21 |
丹娜-法伯癌症研究所 |
通过破坏menin-mll表观遗传复合体靶向治疗胃肠道间质瘤(gist)
|
|
WO2025049521A2
(en)
|
2023-08-28 |
2025-03-06 |
Syndax Pharmaceuticals, Inc. |
Aryl ether analogs as inhibitors of the menin-mll interaction
|